Compare Merck & Co., Inc. (MRK) vs Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Roundhill Innov-100 0DTE Covered Call Strat ETF — how do they compare? Merck & Co., Inc. trades at $129.74 (market cap $321.77B), while Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $29.82. The key difference: Merck & Co., Inc. pays a 2.61% dividend while Roundhill Innov-100 0DTE Covered Call Strat ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Roundhill Innov-100 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals.
| MRK | QDTE | |
|---|---|---|
Market Cap | $321.77B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $131.84 | $36.60 |
52-Week Low | $77.60 | $26.85 |
Enterprise Value | $368.53B | — |
Dividend Yield | 2.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Roundhill Innov-100 0DTE Covered Call Strat ETF
QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →
